Patrick John Finn Sells 10,340 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 10,340 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00. Following the completion of the transaction, the chief operating officer now directly owns 221,061 shares of the company’s stock, valued at approximately $10,610,928. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total value of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total transaction of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $296,636.65.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST traded down $2.77 during trading hours on Wednesday, hitting $42.49. The stock had a trading volume of 962,117 shares, compared to its average volume of 941,048. The stock’s fifty day simple moving average is $43.86 and its 200 day simple moving average is $45.95. Twist Bioscience Co. has a 1-year low of $18.59 and a 1-year high of $60.90.

Institutional Trading of Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in TWST. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the third quarter worth approximately $43,992,000. Point72 Asset Management L.P. raised its stake in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after buying an additional 613,057 shares in the last quarter. Fred Alger Management LLC lifted its holdings in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after buying an additional 575,080 shares during the period. Victory Capital Management Inc. boosted its stake in Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after buying an additional 300,891 shares in the last quarter. Finally, Farallon Capital Management LLC acquired a new position in Twist Bioscience during the second quarter worth about $9,462,000.

Analysts Set New Price Targets

TWST has been the subject of several research analyst reports. Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird lifted their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and an average target price of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.